Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 9/20 | 0.65 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 2/20 | 0.56 |
| ▸ | IL1B | P01584 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 8/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644771 | 0.91 | CASP1 (0.67) | CASP1MMEACEIL1BLCK | |
| SCHEMBL7087544 | 0.91 | CASP1 (0.67) | CASP1MMEACEIL1BLCK | |
| SCHEMBL646584 | 0.91 | CASP1 (0.67) | CASP1MMEACEIL1BLCK | |
| SCHEMBL10263501 | 0.91 | CASP1 (0.67) | CASP1MMEACEIL1BLCK | |
| SCHEMBL14070414 | 0.89 | CASP1 (0.66) | CASP1MMEACEIL1BLCK | |
| SCHEMBL7086870 | 0.89 | CASP1 (0.63) | CASP1MMEACEIL1BLCK | |
| SCHEMBL12809925 | 0.87 | CASP1 (0.59) | CASP1MMEACEIL1BLCK | |
| SCHEMBL2219237 | 0.86 | CASP1 (0.59) | CASP1MMEACEIL1BLCK | |
| SCHEMBL1409094 | 0.86 | CASP1 (0.59) | CASP1MMEACEIL1BLCK | |
| SCHEMBL13776502 | 0.83 | CASP1 (0.77) | CASP1MMEACEIL1BLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-7335792-B2 | Process for synthesizing aspartic and glutamic acid derivatives especially useful as intermediates in the manufacture of a caspase inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-02-26 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CASP1 5/4885MME 327/4885ACE 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.